Moderna names new CCO and expands president's role ahead of product launches
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/22/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
- Emirates refusing to take delivery of first 10 Boeing 777X jets
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- Crude Inventory Rose 2 Million Barrels Last Week - EIA
- Wall St ends higher on chip stocks recovery; earnings in focus
- Palo Alto Networks to acquire Embrace to expand observability tools
Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
June 16, 2026 7:31 AM EDTDr. Stephen Hoge, President of Moderna, to Assume an Expanded Role With Operational Oversight of the Company's Infectious Disease, Intismeran and Rare Disease Franchises
Ester Banque to Join Moderna as Chief Commercial Officer
CAMBRIDGE, MA / ACCESS Newswire / June 16, 2026 / Moderna, Inc. (NASDAQ: MRNA) today announced changes to its operating model to support its short- and long-term business goals.
As Moderna executes its long-range plan to become a diversified, multi-modality biotechnology company, the Company is... More
